

GODAVARI DRUGS LIMITED
Regd. Off.: "Mayfair" S.P.Road, Secunderabad 500003
CIN NO: L24230TG1987PLC008016

Un Audited Financial Results for the Quarter Ended 31.12.2014

Rs. In Lakhs

S.No.	Particulars	UnAudited			UnAudited		Audited
		Quarter Ended			Nine Months Ended		Year Ended
		31.12.14	30.09.14	31.12.13	31.12.14	31.12.13	31.03.14
1	a) Net Sales Income from Operations	1777.73	1495.06	228.14	3995.61	738.63	943.46
	b) Other Operating income	0	0	0	0	0	0
	TOTAL	1777.73	1495.06	228.14	3995.61	738.63	943.46
2	Expenditure:						
	a) Decrease/(Increase) in Stock in trade and Work In Progress	(6.12)	(117.31)	(17.14)	(170.30)	24.39	62.84
	b) Consumption of raw materials	1376.56	1176.56	3.22	3086.75	3.22	51.47
	c) Purchase of trade Goods	0	0	0	0	0	0
	d) Employee Cost	50.75	52.45	37.38	139.87	106.9	146.44
	e) Depreciations	17.08	4.89	26.40	50.89	78.68	104.86
	f) Power & fuel	95.59	88.39	82.13	235.15	216.2	242.89
	g) Other Expenditure	98.26	107.99	75.52	265.23	228.24	255.47
	TOTAL	1632.12	1312.97	207.51	3607.59	657.63	863.97
3	Profit/Loss from Operations before Other Income, Interest and Exceptional Items	145.61	182.09	20.63	388.02	81	79.49
4	Other Income	0.03	0.03	0	0.06	0.45	11.64
5	Profit/Loss before Interest and Exceptional Items	145.64	182.12	20.63	388.08	81.45	91.13
6	Finance Cost	15.31	16.33	5.22	37.99	15.6	20.86
7	Profit/Loss after Interest but before Exceptional Items	130.33	165.79	15.41	350.09	65.85	70.27
8	Exceptional Items	0.00	0.00	0.00	0	0.00	0.00
9	Profit/Loss from Ordinary Activities before Tax	130.33	165.79	15.41	350.09	65.85	70.27
10	Tax Expenses	55.04	58.25	2.94	135.89	12.55	-71.46
	Less: Mat Credit Entitlement	28.18	31.58	2.94	70.05	12.55	13.43
11	Net Profit/Loss from Ordinary Activities after Tax	103.47	139.12	15.41	284.25	65.85	155.16
12	Extraordinary Items (Net of Tax expenses Rs. NIL)	0.00	0.00	0.00	0.00	0.00	0.00
13	Net Profit/Loss for the Period	103.47	139.12	15.41	284.25	65.85	155.16
14	Paid-up Equity Share Capital (Face Value of the Share : Rs. 10)	753.05	753.05	753.05	753.05	753.05	753.05
15	Reserve excluding Revaluation Reserve (as per Balance Sheet) of Previous accounting Year						197.80
16	a) Earning Per Share (EPS) before Extraordinary Items						
	i) Basic EPS (*not annualised)	1.37	1.85	0.20	3.77	0.20	2.06
	ii) Diluted EPS (*not annualised)	1.37	1.85	0.20	3.77	0.20	2.06
	b) Earning Per Share (EPS) after extraordinary Items						
	i) Basic EPS (*not annualised)	1.37	1.85	0.20	3.77	0.20	2.06
	ii) Diluted EPS (*not annualised)	1.37	1.85	0.20	3.77	0.20	2.06
17	Public Share holding						
	No. of Shares	3817639	3926788	4183788	3817639	4183788	3976788
	Percentage of Share Holding	50.70%	52.14%	55.56%	50.70%	55.56%	52.81%
18	Promoters and Promoters Group Share holding						
	a) Pledged/Encumbered Number of Shares	394000	394000	672476	394000	672476	394000
	Percentage of Shares	10.61%	10.93%	20.09%	10.61%	20.09%	11.09%
	(as a% of total share holding of promoters and promoters group)						
	Percentage of Shares	5.23%	5.23%	8.93%	5.23%	8.93%	5.23%
	(as a% of the total share capital of the company)						
	b) Non-encumbered						
	Number of Shares	3318861	3209712	2674236	3318861	2674236	3159712
	Percentage of Shares	89.39%	89.06%	79.91%	89.39%	79.91%	88.91%
	(as a% of the total shareholding of promoter and promoter group)						
	Percentage of Shares	44.07%	42.62%	35.51%	44.07%	35.51%	41.96%
	(as a% of the total share capital of the company)						

Notes:

- The above unaudited financial results were reviewed by Audit Committee and approved by Board of Directors in its meeting held on 11/02/2015. The statutory Auditors have conducted a "Limited Review" of the above Financial Results for the Quarter ended 31st December 2014.
- The Company operated in only one segment viz., APIs (Bulk Drug) & intermediates manufacturing.
- Consequent to the applicability of the Companies Act, 2013 with effect from 1st April, 2014, the company has re-assessed useful life of the fixed assets in accordance with Schedule II, which resulted in decrease in depreciation for the quarter ended and for the nine months ended 31st December, 2014 by Rs. (i) 5.44 lakhs and (ii) 16.46 lakhs respectively. Further Rs. 11.27 lakhs (net of deferred tax) has been adjusted against opening balance of reserve and surplus, representing carrying amount of assets whose remaining useful life is nil as at 1st April, 2014.
- No investors complaint was received during the quarter & no complaint is pending at the beginning and the end of quarter.

for Godavari Drugs Limited

K.K. Jain
K.K. Jain
(Director Finance)

Place: Nanded
Date: 11/02/2015